American Society of Clinical Oncology
225 Reinekers Lane
2064 articles with American Society of Clinical Oncology
New England Journal of Medicine Publishes Final Data for NUBEQA®(darolutamide) Plus Androgen Deprivation Therapy Showing a Statistically Significant Improvement in Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer
The New England Journal of Medicine published the full overall survival results from the pre-specified final OS analysis of the Phase III ARAMIS trial for NUBEQA® in men with non-metastatic castration-resistant prostate cancer.
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced that the American Society of Clinical Oncology has exclusively included Myriad’s myChoice® CDx test in its new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting
Observed clinical activity, including durable and complete tumour responses, suggests that MTL‑CEBPA may increase the effectiveness of sorafenib standard of care
Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
Management to host webcast and conference call to review interim Phase 1 data and provide a pipeline update at 4 p.m. ET /1 p.m. PT on May 29, 2020
BostonGene Announces Acceptance of Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020
Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States
Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting
Data support the initiation of an upcoming first-in-human trial for first-line, MRD+ multiple myeloma patients post-ASCT
Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa‡ targeting TGF-β/PD-L1, in second-line NSCLC
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Informat to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the ASCO
Additional data to be presented validating the SPARE Model for Distant Metastasis Prediction utilizing the Company’s StemPrintER Platform
New data for Sarclisa® (isatuximab-irfc) and Jevtana® (cabazitaxel) in difficult-to-treat cancers reinforce breadth and depth of portfolio
iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Promising clinical research supports Xoft brain IORT as a viable treatment option forglioblastoma multiforme that may extend patients’ lives
Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating NUBEQA® (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
Tiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical Oncology (ASCO) Virtual Conference
Two additional abstracts featuring Milciclib in treating Hepatocellular Carcinoma to be published online
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA® (pembrolizumab) in MSI-H/dMMR Colorectal Cancer
New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis--published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.
NKMax America Announces Acceptance of Three Abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting
NKMax America announced the acceptance of three abstracts for the upcoming 2020 American Society of Clinical Oncology Annual Meeting.
Data highlight a need for bladder-sparing therapies to improve outcomes for patients with high-grade, non-muscle invasive bladder cancer
Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
Lexicon Pharmaceuticals, Inc., announced that data from a poster highlighting XERMELO® will be presented at the American Society for Clinical Oncology 2020 Symposium.
Isofol Medical AB, announced the outcome of an advisory board meeting held to discuss the current status and ongoing strategy for the development of arfolitixorin, the company's proprietary drug candidate being studied in the global pivotal Phase 3 AGENT study for advanced colorectal cancer.